Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.71 |
| ▸ | IMPDH2 | P12268 | 10/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292025 | 1.00 | ROCK2 (0.71) | ROCK2IMPDH2AAK1MAOBROCK1 | |
| SCHEMBL30292024 | 1.00 | ROCK2 (0.71) | ROCK2IMPDH2AAK1MAOBROCK1 | |
| SCHEMBL30292075 | 0.90 | ROCK2 (0.72) | ROCK2IMPDH2AAK1IMPDH1 | |
| SCHEMBL22158336 | 0.90 | ROCK2 (0.72) | ROCK2IMPDH2AAK1IMPDH1 | |
| SCHEMBL22170255 | 0.89 | ROCK2 (0.56) | ROCK2IMPDH2AAK1MAOB | |
| SCHEMBL22165399 | 0.88 | MAOB (0.68) | ROCK2IMPDH2AAK1MAOBIMPDH1 | |
| SCHEMBL30292044 | 0.88 | MAOB (0.68) | ROCK2IMPDH2AAK1MAOBIMPDH1 | |
| SCHEMBL30292017 | 0.88 | MAOB (0.68) | ROCK2IMPDH2AAK1MAOBIMPDH1 | |
| SCHEMBL22158349 | 0.86 | ROCK2 (0.58) | ROCK2IMPDH2AAK1MAOBIMPDH1 | |
| SCHEMBL22158319 | 0.86 | MAOB (0.68) | ROCK2IMPDH2MAOBROCK1IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ENDOGENA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4167999-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | Endogena Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115916192-A | Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved | 内生疗法公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2021257092-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257092-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3902798-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | Endogena Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113227086-A | N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal diseases | 内生疗法公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10807973-B2 | Compounds for use as therapeutically active substances in the treatment of retinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807973-B2 | Compounds for use as therapeutically active substances in the treatment of retinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ALDH1A2, NR2E3, ARRB1 | ROCK2 1702/4885IMPDH2 4338/4885AAK1 3892/4885 |
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | ROCK2 261/4885IMPDH2 4176/4885AAK1 4381/4885 |
| US-12630542-B2 | Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | ALDH1A2, NR2E3, GFRA1 | ROCK2 476/4885IMPDH2 3741/4885AAK1 4424/4885 |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | NR2E3, GFRA2, ALDH1A2 | ROCK2 389/4885IMPDH2 3270/4885AAK1 3347/4885 |
| US-10807973-B2 | Compounds for use as therapeutically active substances in the treatment of retinal diseases | ALDH1A2, NR2E3, ARRB1 | ROCK2 1702/4885IMPDH2 4338/4885AAK1 3892/4885 |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | NR2E3, GFRA2, ALDH1A2 | ROCK2 389/4885IMPDH2 3270/4885AAK1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.